FIL Ltd Has $1.15 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

FIL Ltd reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 69.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,467 shares of the biopharmaceutical company's stock after selling 28,386 shares during the period. FIL Ltd's holdings in Gilead Sciences were worth $1,152,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. McAdam LLC raised its stake in shares of Gilead Sciences by 16.7% in the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after buying an additional 3,627 shares in the last quarter. Capital Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock valued at $35,793,000 after acquiring an additional 9,791 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its stake in shares of Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after purchasing an additional 5,382 shares during the last quarter. Global Financial Private Client LLC boosted its stake in Gilead Sciences by 1,222.0% in the fourth quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock valued at $561,000 after acquiring an additional 5,609 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth $4,192,000. Institutional investors own 83.67% of the company's stock.

Remove Ads

Gilead Sciences Stock Down 0.7 %

Gilead Sciences stock traded down $0.77 during trading on Wednesday, reaching $104.91. 5,304,067 shares of the company's stock were exchanged, compared to its average volume of 7,494,347. The firm has a market cap of $130.63 billion, a price-to-earnings ratio of 283.54, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company's 50-day moving average is $108.63 and its two-hundred day moving average is $97.11.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.01%. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 300,285 shares of company stock valued at $30,274,875 over the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. BMO Capital Markets upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.